Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 5/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886139 | 0.94 | CHEK1 (0.51) | IKBKBCHEK1JAK2JAK3MCHR1 | |
| SCHEMBL1926920 | 0.89 | IKBKB (0.50) | IKBKBCHEK1JAK2JAK3KDM4E | |
| SCHEMBL1928049 | 0.86 | IKBKB (0.49) | IKBKBCHEK1JAK2JAK3KDM4E | |
| SCHEMBL1929412 | 0.85 | CHEK1 (0.51) | IKBKBCHEK1JAK2JAK3MEN1 | |
| SCHEMBL1927981 | 0.84 | IKBKB (0.54) | IKBKBCHEK1JAK2JAK3KDM4E | |
| SCHEMBL1929905 | 0.84 | IKBKB (0.47) | IKBKBCHEK1JAK2JAK3MEN1 | |
| SCHEMBL1929238 | 0.82 | IKBKB (0.48) | IKBKBCHEK1JAK2JAK3MEN1 | |
| SCHEMBL1928260 | 0.81 | IKBKB (0.56) | IKBKBCHEK1JAK2JAK3MEN1 | |
| SCHEMBL1928013 | 0.79 | IKBKB (0.46) | IKBKBCHEK1JAK2JAK3MEN1 | |
| SCHEMBL10371219 | 0.79 | KCNH2 (0.64) | MCHR1OPRK1BCHEKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215829-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | MORLEY ANDREW DAVID | 2009-08-27 | — | — | US | disclosed |
| US-7553868-B2 | Thiophene carboxamides as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2009-06-30 | — | — | US | disclosed |
| EP-1583756-B9 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1583756-B1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| US-20060111431-A1 | Thiophene carboxanmides as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-05-25 | — | — | US | disclosed |
| EP-1583756-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063185-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215829-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | RELA, NFKBIA, CSNK1E | IKBKB 7/4885CHEK1 741/4885JAK2 159/4885 |
| US-20060111431-A1 | Thiophene carboxanmides as inhibitors of the enzyme ikk-2 | RELA, NFKBIA, CHUK | IKBKB 5/4885CHEK1 754/4885JAK2 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.